- Albany Molecular Research (AMRI -13.2%) plunges after an SEC filing shows Bristol-Myers (BMY -1.4%) has terminated the development of the triple reuptake inhibitor BMS-820836.
- According to BMY, the investigational drug failed to show superiority over duloxetine or escitalopram in a Phase II study for Treatment Resistant Depression.
- AMRI says the news will have "no impact on [its] financial guidance or forecasts." (8-K)
at MarketWatch.com (Oct 14, 2014)